Stay updated with breaking news from Topline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2... | February 21, 2023
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 February 2023 - 7.00 AM CET Fagron reports 19% topline growth, 11% increase in REBITDA and free cash flow of €91 million for 2022
The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints
Results from a single ascending dose (SAD) study in healthy volunteers demonstrated dose-proportional PRX005 concentrations in plasma with robust central nervous system (CNS) penetration of this
Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD